Would you consider anifrolumab in the management of hematologic manifestations in SLE?

Hematologic manifestations in SLE vary widely from asymptomatic to life-threatening, from cytopenias to severe bleeding to thrombosis to multiorgan failure. Hematologic manifestations can also be compounded by medications, infections, and co-existing conditions. Each of these manifestations is drive...

I agree with Dr. @Dr. First Last that we are still awaiting more results from the TULIP-1 and TULIP-2 trials on anifrolumab.

However, there is data from the phase II clinical trial, the MUSE trial (Casey et al., PMID 30538817), showing improvements in cytopenias (lymphopenia, neutropenia, and thromb...